At Nagoya University, scientists have coaxed human stem cells into becoming functional pituitary tissue and transplanted it into a primate — a first in medical history. For six weeks, the lab-grown graft produced the hormones a macaque's body could no longer make on its own, offering a glimpse of what medicine might one day offer the millions of people whose pituitary glands have failed them. The achievement does not yet promise a cure, but it marks the moment a door, long imagined, was opened for the first time.
Lab-grown human pituitary tissue successfully transplanted into primate, restoring hormone function
Patients with pituitary failure currently face higher risk of sudden death due to inability of daily hormone pills to match body's natural stress responses.
Lab-grown tissue produced hormones naturally, matching the body's actual needs.
Mark
So they grew a pituitary gland in a lab and put it in a monkey. Did it actually work?
Mimi
It did, for six weeks. The transplanted tissue produced ACTH and cortisol—the hormones the monkey needed—and the animal's condition stabilized. Three months later, living cells from the graft were still there.
Luke
But six weeks is not very long. And they only tested it in one monkey. How much can we really say about whether this will work in humans?
Mimi
That's fair. The point is that this is the first time human stem cell-derived pituitary tissue has survived and functioned in a primate at all. It's a proof of concept, not a finished treatment.
Mark
What's the actual problem they're trying to solve? Why does this matter?
Mimi
Patients with pituitary failure take hormone pills every day for life. But pills can't mimic what the pituitary naturally does—it releases hormones in pulses that change throughout the day and with stress. Pills deliver a fixed dose, which leaves patients either slightly under-treated or over-treated.
Luke
And the consequence of being under-treated is what, exactly?
Mimi
A higher risk of sudden death during acute stress. The body can't produce enough cortisol fast enough to maintain blood pressure and blood sugar.
Mark
So if this works in humans, patients wouldn't need daily pills anymore?
Mimi
That's the hope. A transplanted pituitary tissue could produce hormones naturally, matching the body's actual needs moment to moment.
Luke
But they used immunosuppressive drugs to prevent rejection. Would human patients need to take those drugs forever?
Mimi
Probably, yes. That's one of the things the researchers say they need to work on—finding safer immune-suppression methods before moving to human trials.
Mark
How far away is that?
Mimi
They haven't said. This is still very early research. But the fact that it worked at all in a primate is significant.
Le Pouls
- Patients with pituitary failure face a quiet, daily danger — their hormone pills cannot respond to sudden stress the way a living gland can, leaving them vulnerable to collapse or death at unpredictable moments.
- For the first time, lab-grown human pituitary tissue transplanted into a primate actually worked, raising critical stress hormones to functional levels and stabilizing the animal's deteriorating condition.
- The transplant held for six weeks before the immune system gained the upper hand, yet living donor cells were still detected three months later — a sign of persistence that surprised even the researchers.
- Crucially, no stray cell growth appeared in the monkey's organs, addressing one of the deepest fears surrounding stem cell therapies and clearing a significant safety threshold.
- The Nagoya team now faces the twin challenges of extending tissue survival and refining immune suppression before this proof of concept can begin its long journey toward human clinical trials.
At Nagoya University, scientists have coaxed human stem cells into becoming functional pituitary tissue and transplanted it into a primate — a first in medical history. For six weeks, the lab-grown graft produced the hormones a macaque's body could no longer make on its own, offering a glimpse of what medicine might one day offer the millions of people whose pituitary glands have failed them. The achievement does not yet promise a cure, but it marks the moment a door, long imagined, was opened for the first time.
Researchers at Nagoya University have accomplished something unprecedented: they grew human pituitary tissue from stem cells in a laboratory, transplanted it into a macaque whose own pituitary had been removed, and watched it do the work the missing gland once did. For six weeks, the transplanted organoids produced ACTH and cortisol — the hormones that govern the body's response to stress — returning them to functional levels. The monkey's weight, which had fallen sharply after the surgery, began to stabilize. Three months later, living cells from the graft were still detectable in tissue samples.
The pituitary gland is small but indispensable, sitting at the base of the brain and releasing hormones in precise, shifting pulses that respond to the body's moment-to-moment needs. When it fails, patients are left on daily hormone pills for life — a blunt instrument that delivers fixed doses at fixed times, unable to surge when stress demands it. This gap between what a pill provides and what the body actually needs is not merely inconvenient; it carries a measurably higher risk of sudden death.
Before attempting the primate transplant, the team tested their organoids in mice with surgically removed pituitaries. Placed beneath the skin in fat or muscle tissue, the grafts produced ACTH for more than six months, and the transplanted mice lived significantly longer than untreated controls. No tumors appeared. Encouraged, the researchers moved to the macaque, using immunosuppressive drugs already proven safe in human transplant medicine to hold the immune system at bay.
The strategy bought six weeks of meaningful function before immune rejection gradually overwhelmed the graft. Critically, examination of the monkey's lungs and liver found no signs of stray organoid tissue — a key safety concern with stem cell therapies. Lead author Tatsuma Kondo acknowledged that this was a single-animal study, and that extending tissue survival and developing gentler immune suppression remain the next challenges. The road to human clinical trials is long, but for the first time, lab-grown human pituitary tissue has been shown to survive and function inside a primate body.
A team of researchers at Nagoya University in Japan has achieved something that has never been done before: they grew human pituitary tissue from stem cells in a laboratory, transplanted it into a macaque monkey whose own pituitary gland had been removed, and watched it produce the hormones the animal's body desperately needed. For six weeks, the transplanted tissue worked. It raised levels of ACTH and cortisol—hormones critical for managing stress, blood pressure, and blood sugar—back to functional ranges. The monkey's weight, which had plummeted after the removal of its pituitary, stabilized. Three months after the transplant, tissue samples still contained living cells from the graft, a sign that the transplanted material had taken root despite the body's powerful immune rejection of foreign tissue.
The pituitary gland is a small but consequential organ, sitting at the base of the brain like a master control center. It releases hormones directly into the bloodstream, orchestrating responses to stress and regulating growth and metabolism. When it fails—whether from disease, injury, or surgical removal—the body loses its ability to produce ACTH, the hormone that signals the adrenal glands to release cortisol. Without this signal, a condition called hypopituitarism develops. The body cannot mount an adequate stress response, which can become dangerous. A person under sudden physical or emotional strain may not produce enough cortisol to maintain blood pressure or blood sugar, risking collapse or death.
Currently, patients with pituitary failure take daily hormone pills for the rest of their lives. These medications are a lifeline, but they are also a crude substitute for what the body naturally does. The pituitary releases hormones in pulses that shift with the time of day and with stress itself—more cortisol when you need it, less when you don't. A pill cannot do this. It delivers a fixed dose at fixed times, leaving patients perpetually either slightly under-treated or slightly over-treated. The result is a higher risk of sudden death, particularly during moments of acute stress when the body's demand for cortisol spikes beyond what a pill schedule can provide.
To find a better path forward, the Nagoya team turned to stem cells. They coaxed human stem cells to grow into tiny three-dimensional structures called organoids—miniature organs that contain the specialized cells needed to produce ACTH. Before testing in a primate, they transplanted these organoids into mice whose pituitaries had been surgically removed. The results were encouraging. Placed just under the skin in fat or muscle tissue, the organoids produced ACTH for more than six months. The mice that received the transplants lived significantly longer than those without them. No tumors or abnormal cell growth appeared.
With evidence of safety and function in mice, the team moved to a primate model, a step closer to human biology. They transplanted the organoids into a macaque whose pituitary had been removed. To prevent the monkey's immune system from immediately destroying the foreign human tissue, they used immunosuppressive drugs already proven safe in human transplant medicine—the same drugs given to diabetes patients who receive transplanted insulin-producing cells. The strategy worked well enough. The transplanted tissue elevated ACTH and cortisol in the blood for six weeks. The weight loss that had followed the pituitary removal slowed. But the immune system was relentless. By three months, the transplant had weakened significantly, though some transplanted cells remained alive in tissue samples.
One concern with stem cell therapies is that cells can migrate from the transplant site and grow uncontrollably elsewhere in the body. The researchers examined the monkey's lungs and liver for signs of stray organoid tissue. They found none. Tatsuma Kondo, the first author of the study published in Stem Cell Research & Therapy, noted that the team tested this approach in a single primate and is planning further work to extend how long the tissue survives and to develop safer methods of immune suppression. The path from this proof of concept to a treatment available to human patients remains long. But for the first time, lab-grown human pituitary tissue has been shown to work and persist after transplantation into a primate, opening a door that was previously closed.
Citations marquantes
The organoids were transplanted just under the skin, in fat or muscle tissue. They produced ACTH for more than six months and clearly extended the lifespans of these mice compared to those that did not receive the transplant.— Tatsuma Kondo, first author, Nagoya University
We tested this approach in a single primate and are planning further studies to improve how long the tissue lasts and test safer immune-suppressing methods.— Tatsuma Kondo
Envie de l'histoire complète ?
Lire l'original sur Medical Xpress ↗